ArticleCureus2026
Molecular Interactions Between Dimethylated Arginine and the Nitric Oxide Axis Unveil Programmed Death-Ligand 1 (PD-L1) Signaling Signatures in Gastric Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Gastric cancer (GC) is one of the most common cancers globally. Programmed death cells, a cell-surface molecule, drive arginine dimethylation, disrupting nitric oxide (NO) production in peripheral tissues. Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis disruption depends on dimethylarginine dimethylaminohydrolase 1 (DDAH1) activity during metastasis in patients with severe gastritis, either synergizing with NO or inhibiting PD-1/PD-L1 activation in tumor growth. This study aimed to determine the arginine dimethylation process in conjunction with nitrosative stress, which dysregulates the PD-L1 axis in GC cells. Methodology A cross-sectional study was conducted utilizing real-time polymerase chain reaction for relative mRNA expressions, high-performance liquid chromatography for asymmetric dimethylarginine (ADMA)/symmetric dimethylarginine (SDMA) assays, and spectrophotometry for NO analysis. Statistical tools such as RStudio (version 2024.12.1) were used to conduct principal component analysis, heatmaps, and t-tests/analysis of variance or Mann-Whitney/Kruskal-Wallis tests after Shapiro-Wilk post-hoc tests in different groups (GC, disease control, and healthy control). Results We observed abnormal NO production and reduced mitochondrial DNA copy numbers in GC patients. Significantly decreased levels of ADMA and excessive influx of arginase activity were determined in GC patients. PD-L1 expression was significantly higher in GC patients, while suboptimal PD-L1 expression was associated with disease control. The abnormal influx of dimethylated arginine and matrix metalloproteinase-7 (MMP-7) was associated with and linked to NO production levels. Their association could be with the nitrigenic pathway and with possible mechanisms for damaging cell-surface molecules in GC. Conclusions Overall, the disrupted ADMA-SDMA balance and Ca++ permeability impair the regulation of claudin-4, MMP-7, and PD1/PD-L1 in GC patients. These variables hold promise as diagnostic and therapeutic targets for improved GC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.